Associations of insulin resistance with cardiovascular risk factors and inflammatory cytokines in normal- Weight hispanic women
OBJECTIVE-To investigate the associations of markers of insulin resistance with cardiovascular disease risk factors and inflammation in young, normal-weight, Hispanic women. RESEARCH DESIGNANDMETHODS-Seventy-one normal-weight (BMI < 25 kg/m2) Hispanic women (age, 20-39 years) participated in a fasting blood draw for glucose, insulin, lipids, and inflammatory markers; a glucose tolerance test; anthropometric and blood pressure measurements; body composition by dual-energy x-ray absorptiometry; and measurements of cardiorespiratory fitness via VO2max and daily physical activity by accelerometer. RESULTS-Six percent of participants had impaired fasting glucose, 14% had impaired glucose tolerance, and 48%had at least one cardiovascular disease risk factor.Homeostasismodel assessment of insulin resistance (HOMA-IR) and fasting insulin were positively correlated with glucose, triglycerides, systolic blood pressure, and diastolic blood pressure, and were negatively correlated with adiponectin (P < 0.05). The 2-h insulin was positively correlated with diastolic blood pressure, triglycerides, and high-sensitivity C-reactive protein. HOMA-IR and fasting insulin remained significantly and positively related to glucose, triglycerides, and blood pressure after adjustment for body composition. The relationships between markers of insulin resistance and adiponectin and highsensitivity C-reactive protein were attenuated after adjustment for body composition. CONCLUSIONS-Surrogate markers of insulin resistance were associated with cardiovascular disease risk factors and inflammation in young, normal-weight, Hispanic women. Our findings suggest that HOMA-IR, fasting, and 2-h insulin may be important clinical markers for identifying young, normal-weight, Hispanic women who may be at risk for development of type 2 diabetes and cardiovascular disease. Our findings show the importance of early screening for prevention of type 2 diabetes and cardiovascular disease in this population. © 2013 by the American Diabetes Association.